"Receptor, Endothelin B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of endothelin receptor found predominantly in the KIDNEY. It may play a role in reducing systemic ENDOTHELIN levels.
| Descriptor ID |
D044023
|
| MeSH Number(s) |
D12.776.543.750.695.220.200 D12.776.543.750.750.320.200
|
| Concept/Terms |
Receptor, Endothelin B- Receptor, Endothelin B
- Endothelin B Receptor
- Endothelin B Receptors
- Receptors, Endothelin B
Receptor, Endothelin B, Type 2- Receptor, Endothelin B, Type 2
- Endothelin B-2 Receptors
- Endothelin B 2 Receptors
- Receptors, Endothelin B-2
- Endothelin B-2 Receptor
- Endothelin B 2 Receptor
- Receptor, Endothelin B-2
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Endothelin B".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Endothelin B".
This graph shows the total number of publications written about "Receptor, Endothelin B" by people in this website by year, and whether "Receptor, Endothelin B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Endothelin B" by people in Profiles.
-
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions. PLoS One. 2017; 12(9):e0184154.
-
CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2009 Feb; 36(2):169-75.
-
The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidase [correction of oxidas], ETA, ETB, and MMP9 in the vasculature. J Cardiovasc Pharmacol. 2008 Jul; 52(1):42-8.
-
Developmental expression of endothelin receptors in postnatal swine mesenteric artery. Pediatr Res. 2004 Sep; 56(3):359-65.
-
Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001 Feb 20; 103(7):973-80.
-
Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet. 1999 Apr; 64(4):1216-21.
-
Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate. 1998 Mar 01; 34(4):241-50.
-
Endothelin-B receptor mutations in patients with isolated Hirschsprung disease from a non-inbred population. Hum Mol Genet. 1996 Mar; 5(3):351-4.